SHILPAMEDBSEShilpa Medicare LtdHighNeutral
Announced Fri, 22 May · 14:54 IST

Financial Results

Pat Growth 25pctExceptional ItemResults RestatedRevenue Growth 20pctResults View source PDF

SHILPAMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+8.1%1-day move
₹476.00
prior close
₹511.75
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-2.6-2.9-3.3-6.3+8.1+6.3+3.6+4.0+4.5+8.3+11.9+15.3+28.7
Up moveDown movePending
AI summary

Shilpa Medicare reported strong full-year results with standalone revenue growing 25% to ₹59,703 lakhs and net profit surging 96% to ₹13,297 lakhs. Consolidated revenue rose 20% to ₹153,887 lakhs with net profit jumping over 200% to ₹24,333 lakhs compared to ₹7,830 lakhs last year. EPS on standalone basis improved to ₹6.80 from ₹3.48. Exceptional items turned positive at ₹1,942 lakhs versus a loss of ₹4,574 lakhs in the prior year. The company declared a dividend of ₹0.60 per share. Auditors gave an unmodified (clean) opinion. Key notes include restatement of prior year figures due to a merger and some unaudited foreign subsidiary results included.

Likely market impact

The company delivered exceptional profit growth driven by improved operational performance and positive exceptional items. The clean audit opinion and dividend declaration are positive signals for shareholders. However, investors should note the restated prior year figures and reliance on unaudited data for some foreign subsidiaries.